title: Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761).
authors.affiliation: The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
authors.forename: Mark C
authors.initials: MC
authors.lastname: Gillies
authors.affiliation: The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.
authors.forename: Vincent
authors.initials: V
authors.lastname: Daien
authors.affiliation: The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
authors.forename: Vuong
authors.initials: V
authors.lastname: Nguyen
authors.affiliation: The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Barthelmes
mesh_terms: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D006801:Humans; D008268:Macular Degeneration; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A; D057135:Wet Macular Degeneration
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab